These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 171574

  • 21. Halofenate: a potent inhibitor of normal and hypersensitive platelets.
    Colman RW, Bennett JS, Sheridan JF, Cooper RA, Shattil SJ.
    J Lab Clin Med; 1976 Aug; 88(2):282-91. PubMed ID: 956686
    [Abstract] [Full Text] [Related]

  • 22. [25 years of diabetic treatment by oral hypoglycemic agents: successes and failures].
    Tattersall RB.
    Journ Annu Diabetol Hotel Dieu; 1984 Aug; ():183-91. PubMed ID: 6443219
    [No Abstract] [Full Text] [Related]

  • 23. Letter: Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.
    Daubresse JC, Luyckx AS, Lefebvre PJ.
    N Engl J Med; 1976 Mar 11; 294(11):613. PubMed ID: 1246250
    [No Abstract] [Full Text] [Related]

  • 24. Long-term efficacy of halofenate on serum triglyceride levels.
    Aronow WS, Vicario MD, Moorthy K, King J, Vawter M, Papageorge's NP.
    Curr Ther Res Clin Exp; 1975 Dec 11; 18(6):855-61. PubMed ID: 813950
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.
    Becker ML, Visser LE, Trienekens PH, Hofman A, van Schaik RH, Stricker BH.
    Clin Pharmacol Ther; 2008 Feb 11; 83(2):288-92. PubMed ID: 17597710
    [Abstract] [Full Text] [Related]

  • 28. The effect of halofenate or halofenate free acid on human, rat and guinea pig platelet aggregation.
    Minsker DH, Jordan PT, Kling P, MacMillan A, Hucker HB.
    Thromb Haemost; 1976 Apr 30; 35(2):358-63. PubMed ID: 989636
    [Abstract] [Full Text] [Related]

  • 29. Hypolipidemic effect of tibric acid. A comparison with clofibrate and placebo in type IV hyperlipoproteinemia.
    Bielmann P, Brun D, Moorjani S, Gagnon MA, Tétreault L, Lupien PJ.
    Int J Clin Pharmacol Biopharm; 1977 Apr 30; 15(4):166-71. PubMed ID: 192685
    [Abstract] [Full Text] [Related]

  • 30. Clinical evaluation of a new sulfonylurea in maturity onset diabetes - glipizide (K-4024).
    Bandisode MS, Boshell BR.
    Horm Metab Res; 1976 Mar 30; 8(2):89-91. PubMed ID: 770300
    [Abstract] [Full Text] [Related]

  • 31. Long-term effect of halofenate on serum lipids.
    Aronow WS, Vangrow J, Pagano J, Khemka M, Vawter M, Papageorge's NP.
    Curr Ther Res Clin Exp; 1974 Sep 30; 16(9):897-903. PubMed ID: 4214664
    [No Abstract] [Full Text] [Related]

  • 32. Biguanides. Mode of action and role in the up-to-date treatment of diabetes mellitus.
    Fövényi J.
    Ther Hung; 1971 Sep 30; 19(2):43-8. PubMed ID: 5172874
    [No Abstract] [Full Text] [Related]

  • 33. Altered insulin and glucagon secretion in treated genetic hyperlipemia: a mechanism of theraphy?
    Eaton RP, Oase R, Schade DS.
    Metabolism; 1976 Mar 30; 25(3):245-9. PubMed ID: 1250161
    [Abstract] [Full Text] [Related]

  • 34. Halofenate and clofibrate inhibition of pyruvate dehydrogenase from Fusarium culmorum.
    Madhosingh C, Orr W.
    J Environ Sci Health B; 1985 Apr 30; 20(2):201-14. PubMed ID: 3998411
    [Abstract] [Full Text] [Related]

  • 35. [Effectiveness and tolerance of long-term acarbose therapy in diabetic patients with threatened secondary failure of sulfonylurea drug treatment].
    Domke A, Willms B.
    Med Klin (Munich); 1994 Apr 15; 89(4):187-92. PubMed ID: 8015532
    [Abstract] [Full Text] [Related]

  • 36. [Treatment of primary hyperlipoproteinemias of type IIB and IV with butylbiguanide and clofibrate (author's transl)].
    Koschinsky T, Gries FA, Schwandt P, Weisweiler P, Hansen W, Nijssen J, Beckmann R.
    MMW Munch Med Wochenschr; 1977 May 20; 119(20):701-4. PubMed ID: 195201
    [Abstract] [Full Text] [Related]

  • 37. [Therapy of diabetes in adults using Glibornurid. Results and clinical studies].
    Schöffling K, Mehnert H, Ewald W, Haupt E, Wicklmayr M, Beyer J, Nemeth N.
    Dtsch Med Wochenschr; 1973 May 04; 98(18):915-9. PubMed ID: 4633717
    [No Abstract] [Full Text] [Related]

  • 38. The uricosuric action of halofenate (MK-185) in patients with hyperuricemia or uncomplicated primary gout and hyperlipidemia.
    Hutchison JC, Wilkinson WH.
    Atherosclerosis; 1973 May 04; 18(3):353-62. PubMed ID: 4584481
    [No Abstract] [Full Text] [Related]

  • 39. Effects of halofenate and probenecid on serum lipids and uric acid in hyperlipidemic, hyperuricemic adults.
    Bassett DR, Mikkelsen WM, Buckingham RB, Block WD, Sidiq M, Shakibai A, DiGaetano R, Liou LL.
    Clin Pharmacol Ther; 1977 Sep 04; 22(3):340-51. PubMed ID: 330079
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.